Skip to NavigationSkip to content

News

Novartis has released new data demonstrating the efficacy of Xolair (omalizumab) in the treatment of chronic spontaneous urticaria (CSU), a severe...
The FDA has taken a major first step towards the digitisation of healthcare by approving the reSET app for substance use disorder, created by Pear...
Chinese conglomerate Fosun has agreed to acquire 74% of India’s Gland Pharma for $1.1 billion, sealing a previously unsuccessful deal which was...
The FDA gave Bayer priority review for its treatment Aliqopa (copanlisib) in May of this year, and it quickly came to judgement that the drug should...
Santhera Pharmaceutical has announced the EMA’s CHMP rejected its treatment for Duchenne muscular dystrophy (DMD) but revealed that it planned to...
New CEO for Teva, massive global staff cuts for Lilly, and 'pharma bro' Martin Shkreli finally heads to jail - check out the week's ten most popular...
Pfizer, and its partner Astellas Pharma, received a major boost to its plans for prostate cancer treatment, Xtandi, by announcing it has received...
The FDA has announced the news that it has awarded approval to the first-ever biosimilar for the treatment of cancer in the US – Amgen’s Mvasi (...
GSK, alongside its partner Innoviva, has announced that it has received a positive opinion from the EMA’s CHMP for its Trelegy Ellipta treatment for...
Sandoz has unveiled new Phase 3 data confirming the efficacy and safety profile of its biosimilar adalimumab is on par with its reference product,...
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches